spacer
home > ebr > spring 2018 > therapy at work
PUBLICATIONS
European Biopharmaceutical Review

Therapy at Work

EBR: What is cell therapy?

Dr Daniel Shelly: The use of living human cells as therapeutic treatments can replace lost functionality or introduce a novel function (eg chimeric antigen receptor T-cells to attack tumours). Cell therapies are often classified as either autologous or allogeneic. Autologous cells are obtained from, transformed, and given back to the individual patient, whereas allogeneic cells are sourced from a single donor, grown in large numbers, transformed, and given to multiple patients.

Numerous methods of transformation exist such as using peptides to activate immune cells, using viral vectors to introduce new genetic functions, or gene editing (CRISPR-Cas9) to enhance cellular function. The cell therapy industry is currently at a turning point, driven by significant advances on many fronts, such as a significant amount of product approvals with several more to come, a regulatory recognition of the unique nature of the sector, a financial maturity and investor interest, and finally a general public awareness and interest.

Despite these advances, the sector still needs to optimise several key areas such as manufacture, storage (cryopreservation), formulation, and distribution of such products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Daniel Shelly is Director of business development at Albumedix, responsible for business development and out-licensing of the company’s core technologies and recombinant albumin products for manufacture, stabilisation, and formulation of small molecule, peptide, protein, viral, and cell therapeutics. He spent 10 years in cell culture, vaccine, and gene therapy clinical development and manufacturing. Daniel has authored several peerreviewed articles and book chapters and is an Adjunct Professor in the University of Cincinnati, US, clinical master’s programme, teaching biologics discovery and biotechnology management. He has degrees from Lehigh University (BA), US, The College of William and Mary (MA), US, Florida State (PhD), US, and the University of Cincinnati (MBA), US. Daniel did his post doctorate at the University of California, US, winning the APS Physiological Genomics Fellowship and a National Institutes of Health National Research Service Award.
spacer
Dr Daniel Shelly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement